Dr. Vennapusa is a pathologist working with the US Medical and Scientific Affairs field team supporting internal pharma tissue companion diagnostic assays including PD-L1 (SP142) assay. She served in this role since July 2018. Prior to that she worked at Ventana in Companion Diagnostics division in different roles including as a pathologist, medical director for Ventana’s CAP/CLIA laboratory and as director of clinical operations. During her tenure at Ventana she worked on several translational as well as companion diagnostic IHC, ISH and multiplexing assays as well as on digital pathology algorithms. She served as the lead development pathologist for PD-L1 (SP142) assay since the initiation of its development until the time of marketing of the assay for UC and NSCLC indications. Dr. Vennapusa received her medical education in India where she also trained as a general surgeon. She then pursued a career in pathology in US, where she did her residency in anatomic and clinical pathology (AP/CP) followed by fellowship training in molecular genetic pathology (MGP). She has several publications in molecular pathology and companion diagnostics and also has submitted and was granted patents for her work at Ventana. She has extensive experience in IHC, ISH, digital pathology, PCR, sequencing and NGS based assays.

Dr. Anne Waydelich works at Roche Tissue Diagnostics within the Medical and Scientific Affairs group in the EMEA LATAM region (Europe, Middle East, Africa and Latin America and manages the Roche Tissue Diagnostics EMEA-LATAM Research & Quality control laboratory. She joined Roche (Ventana) in 2001 as customer support representative for the newly created division taking care of research customers (Discovery platforms). Since then, she held various function in the Roche Tissue Diagnostics EMEA-LATAM customer support organization, joining the Medical and Scientific Support function in 2014. She has achieved in 1999 a PhD in Molecular and Cellular Biology at University Louis Pasteur, Strasbourg, France.

Joined Roche last February 2019, as Pathologist in the non-commercial division of the Medical and Scientific Affairs of Roche Diagnostics, Asia Pacific. Previously Associate Pathology Director in a leading global clinical trials organization, Q 2 Solutions (a Quintiles-Quest Joint Venture), Dr. Jara-Lazaro served as Principal Investigator for Companion Diagnostics and Oncology clinical trials in the central lab of its Asia-Pacific hub based in Singapore. Prior to this role, Dr. Jara-Lazaro worked for 7 years in Singapore General Hospital Department of Pathology, subspecialized in Breast and Urologic Pathology, and was Clinical Lead of the Digital Pathology Pilot Project in collaboration with the Singapore Ministry of Health. She has multiple peer-reviewed international publications; and is a manuscript reviewer for several pathology journals. She earned her Medical Degree in University of the East, is a Fellow of the Philippine Society of Pathologists, and Diplomate of the Singapore Academy of Medicine and UK Royal College of Pathologists. A 2 nd generation pathologist, she served in her home-province of Bacolod City after residency training in Philippine General Hospital. She co-headed family- owned clinical and histopath lab, started first FNA clinic in the province, and was faculty of the University of St. La Salle College of Medicine.